|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy显示文摘Background:Parkinson’s disease(PD)is a neurodegenerative disorder whose diagnosis is often challenging because symptoms may overlap with neurodegenerative parkinsonisms.PD is characterized by intraneuronal accumulation of abnormalα-synuclein in brainstem while neurodegenerative parkinsonisms might be associated with accumulation of eitherα-synuclein,as in the case of Multiple System Atrophy(MSA)or tau,as in the case of Corticobasal Degeneration(CBD)and Progressive Supranuclear Palsy(PSP),in other disease-specific brain regions.Definite diagnosis of all these diseases can be formulated only neuropathologically by detection and localization ofα-synuclein or tau aggregates in the brain.Compelling evidence suggests that trace-amount of these proteins can appear in peripheral tissues,including receptor neurons of the olfactory mucosa(OM).Methods:We have set and standardized the experimental conditions to extend the ultrasensitive Real Time Quaking Induced Conversion(RT-QuIC)assay for OM analysis.In particular,by using human recombinantα-synuclein as substrate of reaction,we have assessed the ability of OM collected from patients with clinical diagnoses of PD and MSA to induceα-synuclein aggregation,and compared their seeding ability to that of OM samples collected from patients with clinical diagnoses of CBD and PSP.Results:Our results showed that a significant percentage of MSA and PD samples inducedα-synuclein aggregation with high efficiency,but also few samples of patients with the clinical diagnosis of CBD and PSP caused the same effect.Notably,the final RT-QuIC aggregates obtained from MSA and PD samples owned peculiar biochemical and morphological features potentially enabling their discrimination.Conclusions:Our study provide the proof-of-concept that olfactory mucosa samples collected from patients with PD and MSA possess important seeding activities forα-synuclein.Additional studies are required for(i)estimating sensitivity and specificity of the technique and for(ii)evaluating its application for the diagnosis of PD and neurodegenerative parkinsonisms.RT-QuIC analyses of OM and cerebrospinal fluid(CSF)can be combined with the aim of increasing the overall diagnostic accuracy of these diseases,especially in the early stages. | Chiara Maria Giulia De Luca Antonio Emanuele Elia Sara Maria Portaleone Federico Angelo Cazzaniga Martina Rossi Edoardo Bistaffa Elena De Cecco Joanna Narkiewicz Giulia Salzano Olga Carletta Luigi Romito Grazia Devigili Paola Soliveri Pietro Tiraboschi Giuseppe Legname Fabrizio Tagliavini Roberto Eleopra Giorgio Giaccone Fabio Moda | 2019 | Translational Neurodegeneration2019，8，1： | 5 |
| 3 | The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients显示文摘 | Martijn R. Meijerink Hester Cruijsen Klaas Hoekman Matthijs Kater Cors Schaik Jan Hein T. M. Waesberghe Giuseppe Giaccone Radu A. Manoliu | 2007 | European Radiology2007，，7： | 2 |
| 4 | Novel approaches to the treatment of non-small cell lung cancer显示文摘 | Carlos G Ferreira Cynthia Huisman Giuseppe Giaccone | 2002 | Critical Reviews in Oncology and Hematology2002，，1： | 2 |
| 5 | Multi institutional randomized phase I trial of gefitinib for previously treated patients with advanced non-smallcell lung cancer显示文摘 | Fukuoka M Yano S Giaccone G | 2003 | J Clin Oncol2003，21，12： | 1 |
| 6 | Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer 显示文摘 | Giaccone G | 2005 | J Clin Oncol2005，23，14： | 1 |
| 7 | Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT2显示文摘 | Herbst RS Giaccone G Schiller JH | 2004 | J Clin Oncol2004，22，5： | 1 |
| 8 | Paclitaxel-cisplatin versus teniposide-cisplation in advanced non-small cell lung cancer 显示文摘 | Giaccone G Splinter T Postmus P | 1996 | Proc Am Soc Clin Oncol1996，15，： | 1 |
| 9 | Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial-INTACT1 显示文摘 | Giaccone G Herbst RS Manegold C | 2004 | J Clin Oncol2004，22，5： | 1 |
| 10 | Packet-mode scheduling in input-queued cell-based switches显示文摘 | Marsan M A Bianco A Giaccone P Leonardi E and Neri F | 2002 | IEEE/ACM Transactions on Networking2002，10，5： | 1 |
| 11 | p53 and chemosensitivity显示文摘 | Ferreira CG Tolis C Giaccone G | 1999 | Ann Oncol1999，10，9： | 1 |
| 12 | PhaseⅡstudy of cisplatin preceding gemcitabine in patients with advanced esophageal cancer显示文摘 | Kroep JR Pinedo HM Giaccone G | | 0，，02： | 1 |
| 13 | Vacuum packaging of bovine tripe microbial contamination and indole content显示文摘 | GIACCONE V CIVERA T PARISI E | 1994 | Sciences Des Aliments1994，14，： | 1 |
| 14 | Multi-institutional randonized phase 2trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial)显示文摘 | Fukuoka M Yano S Giaccone G | 2003 | Clin Oncel2003，21，12： | 1 |
| 15 | Src as a potential therapeutic tar-get in non-small-cell lung cancer显示文摘 | Giaccone G Zucali PA | 2008 | Ann Oncol2008，19，7： | 1 |
| 16 | Gemcitabine and paclitaxel :pharmacokinetic and phannacodynamic interactions in patients with non-small-cell lung cancer显示文摘 | Kroep JR Giaccone G Voorn DA | 1999 | J Clin Oncol1999，17，7： | 1 |
| 17 | Geftinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT2 显示文摘 | Herbst RS Giaccone G Schiller JH | 2004 | J Clin Oncol2004，22，5： | 1 |
| 18 | Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer显示文摘 | Fukuoka M Yano S Giaccone G | 2003 | J Clin Oncol2003，21，： | 1 |
| 19 | Randomizedcontrolled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: longterm results 显示文摘 | RebecchiF Giaccone C Farinella E | 2008 | Ann Surg2008，248，： | 1 |
| 20 | Treatment of malignant thymoma显示文摘 | Giuseppe Giaccone | 2005 | Current Opinion in Oncology2005，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员